These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 38021761)
1. The Role of BRAF Inhibitors in the Management of Ameloblastoma: A Literature Review. Malakar A; Kumar VR; Yadav P; Bhardwaj V; Barua CG; Bhardwaj G Cureus; 2023 Oct; 15(10):e47682. PubMed ID: 38021761 [TBL] [Abstract][Full Text] [Related]
2. Current concepts in ameloblastoma-targeted therapies in B-raf proto-oncogene serine/threonine kinase V600E mutation: Systematic review. González-González R; López-Verdín S; Lavalle-Carrasco J; Molina-Frechero N; Isiordia-Espinoza M; Carreón-Burciaga RG; Bologna-Molina R World J Clin Oncol; 2020 Jan; 11(1):31-42. PubMed ID: 31976308 [TBL] [Abstract][Full Text] [Related]
3. BRAF V600E and previously unidentified KRAS G12C mutations in odontogenic tumors may affect MAPK activation differently depending on tumor type. Oh KY; Kim JH; Cho SD; Yoon HJ; Lee JI; Hong SD Genes Chromosomes Cancer; 2022 Aug; 61(8):481-490. PubMed ID: 35353428 [TBL] [Abstract][Full Text] [Related]
4. Detection and evaluation of the presence of the BRAF V600E mutation in ameloblastomas in an Indian population. Goes CF; Spadigam A; Dhupar A; Carvalho KM; Cota J; Syed S Indian J Pathol Microbiol; 2023; 66(2):246-251. PubMed ID: 37077063 [TBL] [Abstract][Full Text] [Related]
6. BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature. Ebeling M; Scheurer M; Sakkas A; Pietzka S; Schramm A; Wilde F Med Oncol; 2023 Apr; 40(6):163. PubMed ID: 37115331 [TBL] [Abstract][Full Text] [Related]
7. Effectiveness of molecular-targeted chemotherapy in ameloblastomas: A systematic review. Yoithapprabhunath TR; Srichinthu KK; Gupta D; Singh D; Pasupuleti S; Nirmal RM Indian J Dent Res; 2022; 33(3):323-331. PubMed ID: 36656197 [TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical analysis of BRAF V600E mutation in ameloblastomas. do Canto AM; da Silva Marcelino BMR; Schussel JL; Wastner BF; Sassi LM; Corrêa L; de Freitas RR; Hasséus B; Kjeller G; Junior CAL; Braz-Silva PH Clin Oral Investig; 2019 Feb; 23(2):779-784. PubMed ID: 29855709 [TBL] [Abstract][Full Text] [Related]
9. The diagnostic utility of BRAF VE1 mutation-specific immunohistochemistry in ameloblastoma. Mendez LD; Wolsefer NS; Asa SL; Wasman J; Yoest JM; Stojanov IJ Mod Pathol; 2022 Nov; 35(11):1570-1577. PubMed ID: 35676332 [TBL] [Abstract][Full Text] [Related]
10. The BRAF p.V600E mutation is a common event in ameloblastomas but is absent in odontogenic keratocysts. Zhang R; Yang Q; Qu J; Hong Y; Liu P; Li T Oral Surg Oral Med Oral Pathol Oral Radiol; 2020 Mar; 129(3):229-235. PubMed ID: 31987674 [TBL] [Abstract][Full Text] [Related]
11. Association of MDM2 Overexpression in Ameloblastomas with Tosios KI; Kalogirou EM; Koutlas IG Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396916 [TBL] [Abstract][Full Text] [Related]
12. Resolution of PTHrP-Mediated Hypercalcemia Following Treatment with Dual BRAF/MEK Inhibition for BRAFV600E-Positive Metastatic Ameloblastoma. Corbett K; Ruether D; Seiden-Long I; Kline G Calcif Tissue Int; 2024 Apr; 114(4):444-449. PubMed ID: 38252285 [TBL] [Abstract][Full Text] [Related]
13. Persistent response to vemurafenib in metastatic ameloblastoma with BRAF mutation: a case report. Broudic-Guibert M; Blay JY; Vazquez L; Evrard A; Karanian M; Taïeb S; Hoog-Labouret N; Oukhatar CMA; Boustany-Grenier R; Arnaud A J Med Case Rep; 2019 Jul; 13(1):245. PubMed ID: 31340860 [TBL] [Abstract][Full Text] [Related]
14. BRAF V600E mutation-specific immunohistochemical analysis in ameloblastomas: a 44-patient cohort study from a single institution. Owosho AA; Ladeji AM; Adebiyi KE; Olajide MA; Okoye ISI; Kehinde T; Nwizu NN; Summersgill KF Eur Arch Otorhinolaryngol; 2021 Aug; 278(8):3065-3071. PubMed ID: 33231757 [TBL] [Abstract][Full Text] [Related]
15. Genetic Study of Kokubun K; Yamamoto K; Akashi Y; Chujo T; Nakajima K; Matsuzaka K Int J Surg Pathol; 2022 Jun; 30(4):378-384. PubMed ID: 34994576 [No Abstract] [Full Text] [Related]
16. Enrichment of SOX2-Positive Cells in BRAF V600E Mutated and Recurrent Ameloblastoma. Tseng CH; Lu PH; Wang YP; Chang JYF J Pers Med; 2022 Jan; 12(1):. PubMed ID: 35055392 [TBL] [Abstract][Full Text] [Related]
17. High frequency of BRAF V600E mutations in ameloblastoma. Kurppa KJ; Catón J; Morgan PR; Ristimäki A; Ruhin B; Kellokoski J; Elenius K; Heikinheimo K J Pathol; 2014 Apr; 232(5):492-8. PubMed ID: 24374844 [TBL] [Abstract][Full Text] [Related]
18. Frequency of BRAF V600E mutation in a group of Thai patients with ameloblastomas. Lapthanasupkul P; Laosuk T; Ruangvejvorachai P; Aittiwarapoj A; Kitkumthorn N Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 Nov; 132(5):e180-e185. PubMed ID: 32665205 [TBL] [Abstract][Full Text] [Related]
19. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers. Roskoski R Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796 [TBL] [Abstract][Full Text] [Related]
20. BRAF-V600E expression correlates with ameloblastoma aggressiveness. Fregnani ER; Perez DE; Paes de Almeida O; Fonseca FP; Soares FA; Castro-Junior G; Alves FA Histopathology; 2017 Feb; 70(3):473-484. PubMed ID: 27681305 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]